Let's start with the Value Creation Plan that we shared at our Capital Markets Day early last year. We're focused on our three key priorities of growth, operations, and people. Our plan is framed by our medium-term financial objectives of 2%-4% core growth, driving 4%-7% EBITDA and 7%-10% EPS growth, all underpinned by free cash flow conversion of 100% or better. Beginning with growth on the left side of the chart, ours was widespread.
All businesses posted positive growth for the quarter and year, and all outgrew their respective markets in Q4, resulting in continued share gains across the portfolio. Consistent with what we've discussed on previous calls, increased new product activity and clinical training are contributing meaningfully to our accelerating growth. We saw record participation in our 2025 employee survey, with broad-based increases in employee engagement. We've redoubled our commitment to talent development, with better than half of all management promotions going to existing employees last year, a 40-point increase over 2024.
Four major new product introductions in Spark last year supported that business's robust growth. New platforms in both premium and challenger contributed to multiple consecutive quarters of growth for our implants franchise and our fastest full-year performance since 2022. In consumables, launches like OptiBond 360, SimpliCore, and CaviCide HP helped propel above-market growth for that business. We posted another strong quarter, delivering good revenue, EBITDA, and EPS growth.